SCHEMBL3544092

SCHEMBL3544092

CCN(CC)CCCC(C)Nc1nc(C=Cc2ccc(OCc3ccccc3)c(OCc3ccccc3)c2)nc2cc(Cl)ccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 2/20 0.64
ERBB4 Q15303 2/20 0.64
CSK P41240 1/20 0.64
CAMK1G Q96NX5 1/20 0.64
FLT3 P36888 5/20 0.63
CCR4 P51679 5/20 0.60
MELK Q14680 4/20 0.52
LYN P07948 1/20 0.52
FGFR1 P11362 1/20 0.52
FER P16591 1/20 0.52
MATK P42679 1/20 0.52
BLK P51451 1/20 0.52
BMX P51813 1/20 0.52
TEK Q02763 1/20 0.52
CAMK2G Q13555 1/20 0.52
CAMK2D Q13557 1/20 0.52
CAMK1 Q14012 1/20 0.52
NPC1 O15118 1/20 0.47
USP2 O75604 1/20 0.47
PRNP P04156 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3544088 1.00 BTK (0.64) BTKERBB4CSKCAMK1GFLT3
SCHEMBL3539191 0.91 CCR4 (0.64) BTKERBB4CSKCAMK1GFLT3
SCHEMBL3539192 0.91 CCR4 (0.64) BTKERBB4CSKCAMK1GFLT3
SCHEMBL3542748 0.88 FLT3 (0.67) FLT3
SCHEMBL3542750 0.88 FLT3 (0.67) FLT3
SCHEMBL3542141 0.85 CCR4 (0.72) BTKERBB4CSKCAMK1GFLT3
SCHEMBL3542142 0.85 CCR4 (0.72) BTKERBB4CSKCAMK1GFLT3
SCHEMBL3536983 0.83 CCR4 (0.66) BTKERBB4CSKCAMK1GFLT3
SCHEMBL3536984 0.83 CCR4 (0.66) BTKERBB4CSKCAMK1GFLT3
SCHEMBL3536852 0.81 FLT3 (0.71) BTKERBB4CSKCAMK1GFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7829566-B2 Such as (7-chloro-2-styryl-quinazolin-4-yl)-(3-imidazol-1-yl-propyl)-amine; glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents MEDERSKI WERNER 2010-11-09 US disclosed
US-20070293667-A1 4-Amino-quinazolines MEDERSKI WERNER 2007-12-20 US disclosed
US-20040044204-A1 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICALS, INC. 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044204-A1 4-amino-quinazolines MRGPRX4, MRGPRX1, MRGPRX2 BTK 1084/4885ERBB4 487/4885CSK 1875/4885
US-20070293667-A1 4-Amino-quinazolines MRGPRX4, MRGPRX1, MRGPRX2 BTK 766/4885ERBB4 601/4885CSK 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.